Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 9/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16284338 | 0.89 | SIRT6 (0.68) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL3534675 | 0.86 | MAPT (0.51) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL22634636 | 0.86 | SIRT6 (0.68) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL27661509 | 0.86 | SIRT6 (0.64) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL10812653 | 0.86 | LMNA (0.64) | MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL3549535 | 0.84 | SIRT6 (0.62) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL22634679 | 0.84 | SIRT6 (0.66) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL10061481 | 0.84 | MAPT (0.66) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL30532598 | 0.82 | SIRT6 (0.75) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL27997682 | 0.82 | SIRT6 (0.75) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | SIRT6 842/4885MAPT 4168/4885MAPK1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.